Market Cap

Hard to Treat Diseases, Inc. Market Capitalization:

CN¥109,646

CNY as of Jan. 1, 2026

US$109,646

business Hard to Treat Diseases, Inc. Company Profile

Hard to Treat Diseases, Inc. Main Stock Listing

OTC: HTDS

Market Capitalization History of Hard to Treat Diseases, Inc.

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Top Competitors by Market Capitalization

Industry: Biotechnology
Company Market Cap (USD)
Novo Nordisk $158.96 B
Vertex Pharmaceuticals Incorporated $115.92 B
CSL Limited $95.75 B
Regeneron Pharmaceuticals, Inc. $82.28 B
Marinomed Biotech AG $70.11 B
Sector: Healthcare
Company Market Cap (USD)
Lilly $968.50 B
Johnson & Johnson $499.57 B
AbbVie $405.28 B
Roche $332.12 B
UnitedHealth Group $304.72 B

Yearly evolution of Hard to Treat Diseases, Inc. market cap

Date Market Cap YoY Change
Jan. 1, 2026 CN¥109,646

Market capitalization is calculated from the opening stock price at the beginning of each year.

Hard to Treat Diseases, Inc. Categories

China languages Healthcare languages Biotechnology
China Healthcare China Biotechnology

Stocks & Indices

Hard to Treat Diseases, Inc. has the following listings and related stock indices.


Stock: OTC: HTDS

What is a company's market capitalization?

The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.